Diabetes

AstraZeneca’s leading diabetes medication could be approved to treat chronic kidney disease for patients with and without type 2 diabetes.

Digital health apps offer solutions to improve diabetes self-management.

Dr. Anthony Fauci addresses the American Heart Association Scientific Sessions.

After an FDA denial and a lost sponsor, sotagliflozin shows it can cut cardiovascular events and possibly treat a form of heart failure that has no approved therapies.

The findings are the first in a series of six studies involving a registry supported by drug makers in the diabetes, cardiovascular, and heart failure space.

Flu increases the risk of heart attack, especially among people with diabetes and atherosclerotic cardiovascular disease (ASCVD). COVID-19 and the possibility of co-infection makes getting vaccinated against the flu particularly important this year.

Drugs block the formation of tiny blood vessels in the retina that are prone to breaking open, resulting in bleeds that can cause serious vision impairment and blindness, explains ADA chief scientific and medical officer, Robert Gabbay, in this conclusion of a four-part video series.

Three healthcare organizations provide models for managing the disease and keeping a close eye on the bottom line.

Patients with diabetic macular edema whose vision remains impaired even with the best available treatments may soon have a combination therapy.

Results from REDUCE-IT trial presented at the ADA meeting show that the fish-oil pill is associated with cardiovascular disease protection among patients with diabetes.

Immediately after the FDA said it found elevated levels of the carcinogenic ingredient N-nitrosodimethylamine (NDMA) in certain extended release (ER) metformin products, the first 2 major recalls are underway.

Americans have been diagnosed with diabetes, mostly with the type 2 variety linked with being overweight or obese.

Several Blues plans have contracted with vendors that supply tech-enabled diabetes disease management and prevention programs. Sometimes the tech is combined with coaching - by a real, live human being.

New plan from CVS Caremark eliminates member cost as a barrier to medications without raising costs for benefits, premiums or deductibles.

A survey of diabetes educators reveals challenges faced by patients with diabetes who can’t afford their drugs.

As people with type 2 diabetes age, the risks of insulin use can outweigh its benefits, creating the need for increased provider and patient education.

Study uncovers specific areas of care that cause concern for Americans with diabetes and opportunities for developing a plan of action.

Downturn in incidence may be partially due to successful public health campaigns to prevent the disease.

How the first oral GLP-1 oral treatment for type 2 diabetes is unique and how it will be priced compared to other GLP-1 medications.

Offering rewards can be a great way to increase member engagement for patients with diabetes.

FDA approved the first and only ready-to-use insulin for IV infusion in hospitals and acute care settings.

FDA granted Fast Track designation to a popular diabetes drug to reduce the risk of cardiovascular death and hospitalization for heart failure in people with chronic heart failure.

While aggressive early intervention may be useful for diabetes patients, that intervention must be sustained.

The leading problems that endocrinologists and educators see from their daily interactions with diabetes patients.

The prevalence of diagnosed diabetes in the United States has remained stable during the past eight years, even as obesity rates climb.

How new technologies are helping patients with diabetes better manage the disease.

Diabetes is one of the nation’s costliest public health emergencies. Here are three fresh approaches that can make a difference.